[{"symbol": "IBRX", "publishedDate": "2026-01-19 11:40:12", "publisher": "Zacks Investment Research", "title": "ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results", "image": "https://images.financialmodelingprep.com/news/immunitybio-shares-surge-on-updated-durable-lymphoma-study-results-20260119.jpg", "site": "zacks.com", "text": "IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.", "url": "https://www.zacks.com/stock/news/2819476/immunitybio-shares-surge-on-updated-durable-lymphoma-study-results?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2819476"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 16:57:23", "publisher": "The Motley Fool", "title": "Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year", "image": "https://images.financialmodelingprep.com/news/stock-market-today-jan-16-immunitybio-soars-after-anktiva-20260116.jpg", "site": "fool.com", "text": "Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.", "url": "https://www.fool.com/coverage/stock-market-today/2026/01/16/stock-market-today-jan-16-immunitybio-soars-after-anktiva-revenue-jumps-700-percent-year-over-year/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 15:45:59", "publisher": "Seeking Alpha", "title": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "image": "https://images.financialmodelingprep.com/news/immunitybio-inc-ibrx-presents-at-44th-annual-jp-morgan-20260116.jpg", "site": "seekingalpha.com", "text": "ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript", "url": "https://seekingalpha.com/article/4860600-immunitybio-inc-ibrx-presents-at-44th-annual-j-p-morgan-healthcare-conference-transcript"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 13:45:22", "publisher": "The Motley Fool", "title": "Why ImmunityBio Stock Is Skyrocketing Again Today", "image": "https://images.financialmodelingprep.com/news/why-immunitybio-stock-is-skyrocketing-again-today-20260116.jpg", "site": "fool.com", "text": "ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies.", "url": "https://www.fool.com/investing/2026/01/16/why-immunitybio-stock-is-skyrocketing-again-today/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 12:52:36", "publisher": "Benzinga", "title": "ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline", "image": "https://images.financialmodelingprep.com/news/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline-20260116.jpg", "site": "benzinga.com", "text": "ImmunityBio Inc. (NASDAQ: IBRX) stock has surged more than 100% year to date after the upbeat fourth-quarter preliminary results and trial data.", "url": "https://www.benzinga.com/news/health-care/26/01/49973099/immunitybio-stock-soars-on-cancer-trial-progress-fda-timeline"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 11:04:51", "publisher": "Benzinga", "title": "ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I\u2011Told\u2011You\u2011So", "image": "https://images.financialmodelingprep.com/news/immunitybios-700-revenue-boom-becomes-citadels-latest-itoldyouso-20260116.jpg", "site": "benzinga.com", "text": "Hedge funds don't need headlines to move \u2014 they need inflection points. ImmunityBio Inc (NASDAQ: IBRX) just delivered one.", "url": "https://www.benzinga.com/markets/hedge-funds/26/01/49969034/immunitybios-700-revenue-boom-becomes-citadels-latest-i%e2%80%91told%e2%80%91you%e2%80%91so"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 10:48:06", "publisher": "Proactive Investors", "title": "ImmunityBio shares rise on positive CAR-NK trial results in Waldenstr\u00f6m lymphoma", "image": "https://images.financialmodelingprep.com/news/immunitybio-shares-rise-on-positive-carnk-trial-results-in-20260116.jpg", "site": "proactiveinvestors.com", "text": "Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable complete responses in patients treated with its off-the-shelf CD19 CAR-NK cell therapy in Waldenstr\u00f6m non-Hodgkin's lymphoma, adding to recent momentum driven by strong sales growth for its approved immunotherapy Anktiva. ImmunityBio said on Friday that follow-up from its ongoing Phase 1/2 QUILT-106 study demonstrated sustained complete responses lasting up to 15 months in evaluable patients, with 100% disease control observed to date.", "url": "https://www.proactiveinvestors.com/companies/news/1085771"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 08:15:00", "publisher": "Proactive Investors - Finance", "title": "Nasdaq, Dow Jones little changed as TSMC settles tech jitters", "image": "https://images.financialmodelingprep.com/news/nasdaq-dow-jones-little-changed-as-tsmc-settles-tech-20260116.jpeg", "site": "proactiveinvestors.com", "text": "1:15pm: Market movers Shares of ImmunityBio (NASDAQ:IBRX) traded more than 30% higher after the company reported updated clinical data showing durable...", "url": "https://www.proactiveinvestors.com/companies/news/1085756/nasdaq-dow-jones-little-changed-as-tsmc-settles-tech-jitters-1085756.html"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 07:00:00", "publisher": "Business Wire", "title": "ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma", "image": "https://images.financialmodelingprep.com/news/immunitybio-announces-durable-complete-response-of-15-months-with-20260116.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combi.", "url": "https://www.businesswire.com/news/home/20260116046721/en/ImmunityBio-Announces-Durable-Complete-Response-of-15-Months-with-a-Chemotherapy-Free-CD19-CAR-NK-Cell-Therapy-in-Waldenstrom-Lymphoma/"}, {"symbol": "IBRX", "publishedDate": "2026-01-16 07:00:00", "publisher": "Business Wire", "title": "ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA\u00ae Plus BCG", "image": "https://images.financialmodelingprep.com/news/immunitybio-advances-firstline-bcg-naive-nmibc-program-with-enrollment-20260116.jpg", "site": "businesswire.com", "text": "CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (.", "url": "https://www.businesswire.com/news/home/20260116479411/en/ImmunityBio-Advances-First-Line-BCG-Naive-NMIBC-Program-with-Enrollment-Exceeding-Expectations-and-Positive-Interim-Analysis-for-ANKTIVA%C2%AE-Plus-BCG/"}]